Biotechnology giant Amgen (AMGN) entered what it calls its “springboard year.” The company is facing a critical transition year with patent expirations and increasing biosimilar competition pressurizing its legacy products. But the company is now ready with a fast-growing portfolio of newer medicines that appears to be reshaping its future growth profile. And Wall Street expects this dividend-paying health care stock to climb roughly 30% from current levels.
Currently, Amgen stock is trading 13% below its 52-week high of $391.29. Let’s find out if this dividend stock is a buy on the dip now.
